Co-Diagnostics, Inc. Adjourns 2026 Annual Meeting After No Quorum

What Happened
Co-Diagnostics, Inc. (CODX) filed an 8-K (Item 5.07) reporting that its 2026 Annual Meeting of Stockholders, originally held on September 3, 2026, failed to achieve a quorum and was adjourned to September 24, 2026. The adjourned meeting on September 24 also lacked a quorum and was again adjourned to September 30, 2026 at 9:00 a.m. Mountain Time. The company announced the reconvened meeting will be held at its offices at 2401 S. Foothill Dr, Ste. D, Salt Lake City, Utah 84109.

Key Details

• Initial Annual Meeting held September 3, 2026; adjourned to September 24, 2026 due to no quorum.
• September 24, 2026 adjourned meeting also lacked a quorum; next reconvened date set for September 30, 2026 at 9:00 a.m. MT.
• Reconvened meeting will follow voting procedures in the definitive proxy statement filed July 21, 2026.
• Proxies already submitted remain valid for the reconvened meeting unless properly changed or revoked before votes are taken.

Why It Matters
Because a quorum was not reached, Co-Diagnostics could not transact business or complete shareholder votes on the scheduled dates. For investors, this delays any shareholder decisions that may affect corporate governance or proposals on the ballot; however, previously submitted proxies will still be counted at the reconvened meeting unless revoked. The company’s bylaws permit the chairperson to adjourn meetings until a quorum is present, which is why the meeting has been rescheduled rather than cancelled.